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hole genome sequencing (WGS) 
technology, which is used to decipher 
the entire genetic code of an individual, 
has recently passed a major milestone. Last year, 
the sequencing technology company Illumina 
announced that they can now sequence an 
individual’s genome for $1,000. This price has 
long been thought of as the one which could make 
it feasible to undertake the widespread adoption 
of WGS as a service of national health systems 
[5]. Media coverage of this technology is 
frequently sensational and focuses on potential 
dangers such as intrusion upon people’s private 
information by the government or insurance 
companies or on eugenics and genetic 
determinism. Thus, the media often overshadow 
more meaningful discussion of how WGS may 
influence our future. It is time for policy makers 
to anticipate the adoption of WGS, and consider 
its potential harms and benefits. 
 
What exactly does WGS promise? Personalized, 
or individualized, healthcare. Current medical 
practice depends on average results from clinical 
trials to determine the optimal treatment for 
diseases. However, with the advent of 
personalized healthcare, patients are beginning 
to receive drugs that are predicted to be most 
effective or give the least side effects based on 
their genetics. Additionally, WGS could be of 
benefit for preventive medicine by revealing 
diseases patients are genetically predisposed to, 
allowing doctors to recommend appropriate 
lifestyle changes for patients. An especially 
controversial potential use of WGS is as part of 
routine screening of newborns or foetuses. 
Based on WGS information, parents, or those 
soon to become parents, could make decisions 
about the future of their child or foetus, for 
example regarding plans for the child’s lifestyle 
or whether to terminate a pregnancy. 
 
The challenge for policy makers is to put a 
framework in place that allows these promises to 
be delivered in ways that maximize their benefits 
and minimize harms. Unfortunately, there is little 
helpful information available to the public to give 
an unbiased portrayal of the issues WGS poses 
for us. However, in parallel with sensational 
stories in the media, an unofficial yet fruitful 
conversation between biomedical scientists, 
doctors, and social scientists has been growing 
quickly.  
With the advent of personalized healthcare, 
patients are beginning to receive drugs that 
are predicted to be most effective or give 
the least side effects based on their genetics. 
Below, I have summarized central issues covered 
in these discussions, including challenges of 
interpreting genomic data, lack of genomic 
education in healthcare systems, ethical issues 
surrounding incidental findings, newborn or 
infant screening, and privacy/data storage 
issues. Available research consensus and policy 
positions from notable organizations are included 
as well. 
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Practical Issues 
Current effort involved in genome sequence 
analysis 
Sequencing technology has matured rapidly; 
analysis of the resulting data is now the 
bottleneck that needs to be resolved. Currently, 
sequencing data can only be analysed by experts 
with the help of complex computational tools. If 
WGS is to become a common medical test, the 
analysis methods for the test results need to 
develop apace. These methods need to become 
faster and easier to use so that analysis can take 
place at the required scale. Additionally, although 
an individual’s genome can be sequenced for 
$1,000, this price does not take into account the 
specialized analysis required. While the cost of 
analysis is difficult to estimate, at the moment it 
may well increase the total price several-fold. 
 
Lack of education of health care professionals 
Many patients, and even clinicians, view genetics 
as highly deterministic, when in reality this is not 
usually the case. Often, a mutation will increase 
the likelihood of a disease manifesting itself in a 
person by only a small amount. Genomic 
medicine is currently not typically included in 
medical, nursing, or other healthcare curricula, 
and even if it were added now, the challenge of 
educating existing healthcare workers remains. 
To improve education, questions on genomic 
medicine could be included on board and 
licensing exams. Also concerning is the 
inadequate number of genetic counsellors. For 
WGS to successfully become a widespread test, 
professionals are needed that can counsel 
patients on their results. Employing these 
counsellors would also further increase the total 
price of WGS. 
 
Cost and security of data storage 
The process of sequencing an individual’s 
genome produces a large amount of 
computational data that requires tens of 
gigabytes of memory. The data of just a small 
number of genomes would overwhelm a laptop or 
desktop computer, which is why expensive 
servers are needed to handle central storage. If 
WGS were performed for a significant percentage 
of the population, the storage costs would be 
substantial. This in turn would drive up the price 
of WGS as a medical test. Privacy is also an issue. 
Concern has been raised about companies 
gaining insight into an individual’s genetic 
makeup to help decide whether they will hire 
them, and about insurance companies accessing 
WGS data to make decisions about coverage for 
an individual. Therefore great care must be taken 
to ensure patient data is stored securely.  
 
Ethical Issues 
Interpretation and incidental findings 
Scientists have spent decades compiling 
databases of genetic mutations that are 
associated with diseases, which are becoming 
more comprehensive every year. But some of 
this research is of insufficient quality, mostly in 
earlier studies performed when research 
methodologies were less reliable. Scientists 
estimate that 25% of reports linking a gene to a 
disease are incorrect (Bell, 2011). It is essential 
that the only mutations flagged as harmful in WGS 
tests are those supported by broad scientific 
consensus to have a role in disease. Otherwise, 
patients could falsely be told they may develop a 
serious disease, potentially causing them 
psychological harm and making healthcare 
professionals targets of malpractice lawsuits. 
 
When a patient has their genome sequenced, it is 
possible that an unexpected disease-associated 
mutation may be found. For example, the 
sequencing of a cancer patient’s genome to 
determine the optimal drug for them may also 
uncover that they are likely to have Alzheimer’s 
disease when they are older.  
 
In other medical tests, incidental findings are 
usually shared with the patient – if a radiologist 
sees a tumour underneath a cloud of pneumonia 
on an x-ray film, the patient will be alerted and 
provided appropriate care. But in most tests, 
these incidental findings are relatively rare. WGS 
is different: the genome contains 20,000 genes, 
thousands of which can contain disease-
associated mutations (Hamosh, 2005). The 
chance of seeing something unexpected is much 
higher in each patient. 
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The best way to handle these incidental findings 
is under debate in scientific and medical 
communities, since clinicians will need clear 
ethical guidelines for their practice. The debate 
is about protecting the patient, whilst also 
respecting their ability to control their health and 
have all the information they want, which medical 
ethicists refer to as patient autonomy. Often it is 
suggested to only return incidental findings that 
can be addressed, that is findings regarding 
diseases that can be prevented or cured.  
 
Some research has been conducted investigating 
how much information people would like to learn 
about their genome. Middleton et al. interviewed 
hundreds of individuals to find out their thoughts 
when hearing their incidental findings from a 
WGS test. Most wanted the information, 
especially if it concerned diseases for which 
cures or preventive treatments exist. However, 
it has also been shown that individuals do not 
modify their behaviour when they become aware 
of genetic risks they face (Hollands, 2016). More 
large-scale studies need to be done to confirm 
these findings, as has been done for incidental 
findings from imaging tests. 
There is dispute over whether to give 
children knowledge of a disease they will or 
are likely to develop as adults. This needs to 
be resolved…  
Professional organizations have set out 
recommendations for clinicians and 
policymakers. For the full explanations I 
recommend the original documents, but I have 
summarized some of the main points: 
 
American College of Medical Genetics (ACMG)  
•   Supports patient autonomy 
•   Recommends adequate pre-test 
counselling and informed consent to see 
if the patient would like to receive 
incidental findings 
•   Recommends that only mutations known 
with certainty are returned – those with 
tests that can confirm them, are 
preventable, and have treatments 
•   Incidental findings should be returned 
regardless of age 
 
Association of Genetic Nurses and Counsellors 
(AGNC) 
•   Supports patient autonomy 
•   Incidental findings for adult-onset 
diseases should not be returned to 
children 
•   Recommends that a pre-determined list 
of mutations be made. This list should be 
well-validated scientifically, and 
mutations should only be involved in 
diseases that are serious or life-
threatening and for which there are 
interventions or preventative strategies 
available 
 
Genome screening of foetuses or newborns 
There is dispute over whether to give children 
knowledge of a disease they will or are likely to 
develop as adults. This needs to be resolved, as 
many propose using WGS on all newborns as part 
of newborn screening. 
 
In the UK, newborns are screened for conditions 
such as congenital heart defects, cystic fibrosis, 
and sickle cell disease. Screening programs are 
highly scrutinized by regulatory agencies to 
ensure quality and cost-effectiveness.  
 
A practical problem with screening all newborns 
by WGS is the total cost for the healthcare 
system. The big question is whether any 
incidental findings made about each newborn 
would need to be followed up by doctors to 
validate them and prescribe treatments 
accordingly. The costs of doing so are difficult to 
estimate, but are likely prohibitive (Beckmann, 
2015). 
 
A contentious issue is involved in testing fetuses. 
In response to WGS screening results, expecting 
parents could have the ability to terminate a 
pregnancy if the foetus does not have the genetic 
traits they want. Although this is a choice many 
expecting parents already must make for 
conditions such as Downs Syndrome (for which a 
blood test exists that is elective in the UK), it 
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remains an area of controversy. Once we know 
more about how genetics influences complex 
traits like intelligence or athletic ability, WGS 
information will not only be informative about the 
future health of the foetus, it may in theory also 
be used to predict how smart or good at sports a 
child could become. 
 
The AGNC recommends that opportunistic 
genomic screening should be available to all 
children and adults. However, others have 
cautioned that little research has been conducted 
to understand how parents and children may 
react to undesirable results. Until more is known 
about the benefits and harms of using WGS as a 
screening tool, it may be best to use it only when 
needed to diagnose a disease.  
 
Recommendations 
 
I.   Policy makers should recognize the potential 
benefits of genome sequencing for public 
health but also take into account and address 
ethical and practical issues. 
II.   Legislation should be considered concerning 
issues of adoption of WGS into the NHS, 
return of results to patients, and data storage. 
Specifically, funding for WGS tests, 
guidelines for providing WGS tests and their 
results to patients, privacy issues, and 
protection from genetic discrimination need 
to be addressed. See Knoppers et al. (2015) 
for a comprehensive list of policy 
recommendations made by professional 
organizations and legislation passed in 
several countries. 
III.   Funding should be continued for quality 
research to find cures or preventive 
measures for various genetic diseases as 
well as to uncover new disease-associated 
genetic traits. Furthermore, funds should be 
allocated for studies that will re-examine 
genes reportedly linked to diseases, so that 
false links can be eliminated. In addition to 
these genetics studies, social science 
investigations into the psychosocial effects 
and ethics of WGS testing are important and 
should receive funding as well.  
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